title: Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
abstract: Thalidomide is successfully used in the treatment of multiple myeloma, leprosy and various autoimmune diseases due to its anti-angiogenic, immunomodulatory and anti-inflammatory effects. Thalidomide's most common side effects are constipation, neuropathy, fatigue, sedation, rash, tremor and peripheral edema. We achieved complete response with a 400 mg/day dose thalidomide therapy in a 58-year-old male patient diagnosed with relapsing refractory multiple myeloma. While continuing thalidomide for sustainable response, the therapy was terminated at the ninth month due to development of leukocytoclastic vasculitis. We describe the case and discuss the place of thalidomide in the treatment of multiple myeloma and the rare occurrence of leukocytoclastic vasculitis during thalidomide therapy in multiple myeloma, since only one such case has been reported in the literature thus far.
authors: Division of Hematology, Department of Internal Medicine, University, Istanbul, Turkey. ty@ttnet.net.tr
authors: Naciye Demirel
authors: ND
authors: Yildirim
authors: Mesut
authors: M
authors: Ayer
authors: Reyhan Diz
authors: RD
authors: Küçükkaya
authors: Nilüfer
authors: N
authors: Alpay
authors: Ozgür
authors: O
authors: Mete
authors: Mustafa Nuri
authors: MN
authors: Yenerel
authors: Akif Selim
authors: AS
authors: Yavuz
authors: Meliha
authors: M
authors: Nalçaci
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000009:adverse effects; D004164:Diphosphonates / Q000009:adverse effects; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D012008:Recurrence; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects*; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced* / Q000175:diagnosis* / Q000473:pathology; D000077211:Zoledronic Acid
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D013792:Thalidomide; D000077211:Zoledronic Acid